tepoxalin

Also Known As:

5-(4-chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-1H-pyrazole-3-propanamide; ORF 20485; ORF-20485; 1H-Pyrazole-3-propanamide, 5-(4-chlorophenyl)-N-hydroxy-1-(4-methoxyphenyl)-N-methyl-

Networked: 30 relevant articles (3 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - tepoxalin: 30

Experts

1.	Bushey, J J: 2 articles (06/2016 - 09/2012)
2.	Wakshlag, J J: 2 articles (06/2016 - 09/2012)
3.	Budsberg, Steven C: 2 articles (09/2008 - 06/2005)
4.	Reynolds, Lisa R: 2 articles (09/2008 - 06/2005)
5.	Bild, Andrea H: 1 article (10/2021)
6.	Chang, Jeffrey T: 1 article (10/2021)
7.	Chen, Jinfeng: 1 article (10/2021)
8.	McQuerry, Jasmine A: 1 article (10/2021)
9.	Ben-David, Uri: 1 article (01/2020)
10.	Bender, Samantha A: 1 article (01/2020)

Related Diseases

1.	Neoplasms (Cancer) 10/01/2021 - "Further study is warranted to ascertain the clinical potential of tepoxalin, an FDA-approved therapeutic for use in domesticated mammals, to restore chemosensitivity and improve drug response in patients with ABCB1-overexpressing drug-resistant breast cancers." 01/01/2018 - "We evaluated Tepoxalin (TPX) a dual 5-LOX-COX inhibitor and Erlotinib (ERB) an EGFR inhibitor alone and combination in MGC-803 injected tumor xenografts mice. " 09/01/2012 - "The lack of nuclear staining in primary and xenografted tumors and the lack of response to eicoasanoids suggest that lipid mediator production is not the primary means by which tepoxalin acts to alter proliferation. " 09/01/2012 - "Surprisingly, a canine 5-lipoxygenase inhibitor (tepoxalin) significantly reduced cell proliferation at physiologic doses in vitro and diminished xenograft tumor growth in nude mice, suggesting that further investigation is needed. " 01/01/2018 - "Tepoxalin a dual 5-LOX-COX inhibitor and erlotinib an EGFR inhibitor halts progression of gastric cancer in tumor xenograft mice."
2.	Inflammation (Inflammations) 06/01/2000 - "Tepoxalin inhibits inflammation and microvascular dysfunction induced by abdominal irradiation in rats." 06/01/2000 - "Tepoxalin affords significant protection against radiation-induced inflammation and microvascular dysfunction in splanchnic organs through a mechanism dependent on leukotriene synthesis inhibition." 12/01/1993 - "The ability of tepoxalin to suppress inflammation without causing gastric mucosal injury appears to be related to its differential suppression of prostaglandin synthesis in various tissues. " 01/01/2004 - "Tepoxalin is approved in the United States for control of pain and inflammation associated with arthritis and in Europe for relief of pain caused by musculoskeletal disorders. " 06/01/1997 - "These data suggest that LO inhibition may play a vital role in the prevention of NSAID-induced gastric inflammation, providing insight into the lack of ulcerogenicity with tepoxalin and new approaches to anti-inflammatory therapy which may prevent gastric side effects."
3.	Pruritus (Itching) 08/01/2009 - "Analysis of pooled data indicated that tepoxalin resulted in a significant reduction in pruritus (P = 0.012) and mCADESI-01 (P = 0.002) scores but there was no significant change after placebo. " 08/01/2009 - "The median pruritus scores before and after tepoxalin were 2 (range 1-5) and 1 (range 0-5), respectively, and before and after placebo were 2 (range 0-4) and 2 (range 0-4), respectively. " 08/01/2009 - "After administration of tepoxalin there was a > or = 50% reduction in pruritus and mCADESI-01 scores in 36% and 25% of the dogs, respectively, whereas following administration of the placebo there was a > or = 50% reduction in pruritus and mCADESI-01 scores in only 25% and 16% of the dogs, respectively. " 08/01/2009 - "Tepoxalin reduces pruritus and modified CADESI-01 scores in dogs with atopic dermatitis: a prospective, randomized, double-blinded, placebo-controlled, cross-over study."
4.	Breast Neoplasms (Breast Cancer) 10/01/2021 - "Tepoxalin increases chemotherapy efficacy in drug-resistant breast cancer cells overexpressing the multidrug transporter gene ABCB1." 10/01/2021 - "Several breast cancer cell lines with inducible ABCB1 expression demonstrated sensitivity to the 5-lipoxygenase, cyclooxygenase-1/2 inhibitor tepoxalin in two-dimensional drug response assays, and combination treatment of tepoxalin either with chemotherapies or with histone deacetylase (HDAC) inhibitors improved therapeutic efficacy in these lines. "
5.	Osteoarthritis 06/01/2013 - "Tepoxalin may be used, with appropriate monitoring, in dogs with International Renal Interest Society stage 2 or 3 CKD and osteoarthritis." 06/01/1998 - "Antiinflammatory effect of tepoxalin: blood and synovial tissue studied in patients with knee arthrosis." 06/01/2013 - "Acute and chronic effects of tepoxalin on kidney function in dogs with chronic kidney disease and osteoarthritis." 06/01/1998 - "Our aim was to determine the amounts of eicosanoids in blood and synovial tissue of patients with knee arthrosis and to examine the effects of 2 doses of tepoxalin (50 mg twice, 200 mg twice), administered p.o. " 07/22/2009 - "To study the ability of tepoxalin, a dual inhibitor of cyclooxygenase (COX) and lipoxygenase (LOX) and its active metabolite to reduce the catabolic response of cartilage to cytokine stimulation in an in vitro model of canine osteoarthritis (OA).Grossly normal cartilage was collected post-mortem from seven dogs that had no evidence of joint disease. "

Related Drugs and Biologics

1.	Arachidonate 5-Lipoxygenase (5 Lipoxygenase)
2.	Leukotrienes
3.	Histone Deacetylase Inhibitors
4.	Cyclooxygenase 1
5.	Histone Deacetylases (Histone Deacetylase)
6.	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
7.	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
8.	Lipoxygenase (Lipoxygenase-1)
9.	Cytokines
10.	Indomethacin (Indometacin)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Anesthesia
3.	Therapeutics
4.	Premedication